Yahoo Finance: AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 The Mirror: Ovarian cancer breakthrough as patients who take pill 'less likely to die' A drug for a rare disease may extend the lives of ovarian cancer patients, a new trial has suggested. Patients with a certain type of ovarian cancer may also benefit by taking a drug for Cushing’s ... Ovarian cancer breakthrough as patients who take pill 'less likely to die' MedPage Today: Radon and Ovarian Cancer; Melanoma Drug Rejected; Missed Chances for Genomic Testing High levels of residential radon were linked to a roughly 30% higher risk for ovarian cancer in postmenopausal women, an analysis of the Women's Health Initiative showed.
( JAMA Network Open) ... Radon and Ovarian Cancer; Melanoma Drug Rejected; Missed Chances for Genomic Testing SAN JUAN, PUERTO RICO -- A novel regimen for platinum-resistant ovarian cancer solidified its role as a treatment option with a significant improvement in overall survival (OS), according to a ROSELLA ... A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s unusually fast and aggressive spread. AOL: Drug for rare disease could be used to extend lives of ovarian cancer patients, study finds A drug typically used for a rare disorder could extend the lives of patients battling a form of ovarian cancer, a study has found.
what is ovarian cancer, Women diagnosed with platinum-resistant ovarian cancer, a type where ... Drug for rare disease could be used to extend lives of ovarian cancer patients, study finds SurvivorNet on MSN: Newly approved ovarian cancer treatment combination with the drug Lifyorli helps give time after relapse The FDA has approved Lifyorli (relacorilant) plus Abraxane for certain platinum‑resistant ovarian cancer patients, offering a new option after prior treatments stop working. Newly approved ovarian cancer treatment combination with the drug Lifyorli helps give time after relapse Cancer Therapy Advisor: Mortality Risk Steadily Declines for Long-Term Ovarian Cancer Survivors Investigators compared mortality risk among long-term survivors of high-grade serous ovarian cancer versus the general US population to examine how mortality and recurrence trends have changed with ... MarketWatch: Zentalis Pharmaceuticals Climbs on Selection of Higher Dose for Ovarian-Cancer Trials Shares of Zentalis Pharmaceuticals rose after the company selected a higher dose of azenosertib to treat ovarian cancer in two clinical trials. The stock gained 49%, to $4.12, Thursday afternoon after ...
